The elusive goal of selecting the right number and type of genes for breast and ovarian cancer pharmacodiagnostics can be achieved in future by application of pathology-supported genetic testing extending from BRCA1/2 founder variant screening to multigene panel testing complemented by WES/WGS in genetically uninformative cases. Here, BRCA1 is linked to ovarian cancer.